Claudio Campa * Pages 1194 - 1200 ( 7 )
This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab.
Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
Anti-VEGF, conbercept, brolucizumab, port delivery system, ranibizumab, abicipar pegol, faricimab.
Eye Clinic, Sant'Anna University Hospital, Ferrara